{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:16:25Z","timestamp":1783041385670,"version":"3.54.6"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0630-4","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T12:37:29Z","timestamp":1529930249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Targeting ERBB2 mutations in solid tumors: biological and clinical implications"],"prefix":"10.1186","volume":"11","author":[{"given":"Sophie","family":"Cousin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Crombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yech\u2019an","family":"Laizet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Toulmonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvestre","family":"Le Moulec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Auzanneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"630_CR1","first-page":"4","volume":"6","author":"S Rose","year":"2016","unstructured":"Rose S. Huge data-sharing project launched. Cancer Discov. 2016;6:4\u20135.","journal-title":"Cancer Discov"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-017-0411-5","volume":"10","author":"S Cousin","year":"2017","unstructured":"Cousin S, Grellety T, Toulmonde M, Auzanneau C, Khalifa E, Laizet Y, et al. Clinical impact of extensive molecular profiling in advanced cancer patients. J Hematol Oncol. 2017;10:45.","journal-title":"J Hematol Oncol"},{"key":"630_CR3","doi-asserted-by":"publisher","first-page":"a001263","DOI":"10.1101\/mcs.a001263","volume":"2","author":"R Biswas","year":"2016","unstructured":"Biswas R, Gao S, Cultraro CM, et al. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an \u201cexceptional responder\u201d lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Cold Spring Harb Mol Case Stud. 2016;2:a001263.","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"630_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189\u201394.","journal-title":"Nature"},{"key":"630_CR5","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1158\/1535-7163.MCT-15-0383","volume":"14","author":"S Lopez","year":"2015","unstructured":"Lopez S, Cocco E, Black J, et al. Dual ERBB2\/PIK3CA targeting overcomes single-agent acquired resistance in ERBB2-amplified uterine serous carcinoma cell lines in vitro and in vivo. Mol Cancer Ther. 2015;14:2519\u201326.","journal-title":"Mol Cancer Ther"},{"key":"630_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2159-8290.CD-16-1431","volume":"7","author":"AB Hanker","year":"2017","unstructured":"Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, et al. An acquired ERBB2T798I gatekeeper mutation induces resistance to neratinib in a patient with ERBB2 mutant-driven breast cancer. Cancer Discov. 2017;7:575\u201385.","journal-title":"Cancer Discov."}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0630-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T23:34:13Z","timestamp":1561419253000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0630-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"2 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"86"}}